Health Score

0 Fair

Metadata coverage

Abstract

ORCID

References

License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder

Award / grant

Affiliation & institutional identifiers

Affiliation

ROR ID

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

Attach ORCID iDs across 22 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

High impact22 DOIs

Add abstracts to 19 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

Medium impact19 DOIs

Deposit reference lists for 19 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Medium impact19 DOIs

DOIs for this ISSN

Showing the top 5 of 32 DOIs, ordered by correction priority.

#	Title	Missing	Priority	Citations
1	The breakthrough and the future: CD20 chimeric antigen recep… (10.1002/imed.1039)	ORCID	26.03	10
2	The effects of tumor‐derived exosomes on T‐cell function and… (10.1002/imed.1029)	ORCID	19.45	5
3	Comparing VIP and PD‐L1 expression as cancer biomarkers (10.1002/imed.1033)	ORCID	17.47	4
4	Infections in hematologic malignancy patients treated by CD1… (10.1002/imed.1036)	ORCID	15.05	3
5	Programmed death‐ligand 1 expression in Epstein‐Barr virus p… (10.1002/imed.1042)	ORCID	7.53	1
6	The cross‐disciplinary intellectual stream of <i>ImmunoMedic… (10.1002/imed.1009)	Abstract References ORCID	0.00	0
7	My new normal: A patient's perspective on polymyalgia rheuma… (10.1002/imed.1010)	Abstract References	0.00	0
8	<i>Simply Science</i>: The Eighth Annual Bone Marrow Transpl… (10.1002/imed.1011)	References	0.00	0
9	Next Generation Therapeutic Strateg‐Es: <i>Evolving</i> canc… (10.1002/imed.1020)		0.00	6
10	Neoantigen‐based vaccines as a promising strategy in cancer… (10.1002/imed.1021)		0.00	1
11	Therapeutic dendritic cell cancer vaccines in hematologic ma… (10.1002/imed.1022)		0.00	0
12	Issue Information (10.1002/imed.1023)	Abstract References ORCID	0.00	0
13	Issue Information (10.1002/imed.1024)	Abstract References ORCID	0.00	0
14	Whole tumor cell vaccines engineered to secrete GM‐CSF (GVAX… (10.1002/imed.1025)		0.00	26
15	Vaccination for cancer: Myth or reality (10.1002/imed.1026)	Abstract	0.00	0
16	Comprehensive approach for identification of functional <i>F… (10.1002/imed.1027)		0.00	0
17	Understanding immunotherapy terminology: An analysis of prov… (10.1002/imed.1028)		0.00	6
18	Non‐BCMA targeted CAR‐T cell therapies for multiple myeloma (10.1002/imed.1030)		0.00	5
19	Chimeric antigen receptor‐engineered adoptive cell therapy f… (10.1002/imed.1031)		0.00	0
20	HLA‐matched allogeneic anti‐CD19 CAR‐T therapy in treating a… (10.1002/imed.1032)		0.00	0
21	CAR T cell therapy in advanced B‐ALL with heavy disease burd… (10.1002/imed.1037)	ORCID	0.00	0
22	Special issue: CAR‐T cell therapy for hematological malignan… (10.1002/imed.1038)	Abstract References	0.00	0
23	Issue Information (10.1002/imed.1040)	Abstract References ORCID	0.00	0
24	Metabolic inhibitor screening identifies dihydrofolate reduc… (10.1002/imed.1041)		0.00	1
25	Issue Information (10.1002/imed.1043)	Abstract References ORCID	0.00	0
26	Purinergic signaling and purine base metabolism at the cross… (10.1002/imed.1044)		0.00	3
27	Issue Information (10.1002/imed.1045)	Abstract References ORCID	0.00	0
28	Issue Information (10.1002/imed.1050)	Abstract References ORCID	0.00	0
29	The use of transcriptomic data in developing biomarkers in b… (10.1002/imed.1051)		0.00	0
30	Engineered immunologic niche monitors checkpoint blockade re… (10.1002/imed.1052)		0.00	2
31	Longitudinal monitoring of T cell dynamics in metastatic bre… (10.1002/imed.70000)		0.00	1
32	Issue Information (10.1002/imed.70001)	Abstract References ORCID	0.00	0